Sequence variants and haplotype analysis of cat ERBB2 gene: A survey on spontaneous cat mammary neoplastic and non-neoplastic lesions

International Journal of Molecular Sciences

Volumn 13, Issue 3, 2012, Pages 2783-2800

  Santos, Sara ^a   Bastos, Estela ^a   Baptista, Cláudia S ^a,b   Sá, Daniela ^a   Caloustian, Christophe ^c   Guedes Pinto, Henrique ^a   Gärtner, Fátima ^b   Gut, Ivo G ^c   Chaves, Raquel ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c DIF   (France)

Author keywords

Cat mammary tumors (CMT); Haplotypes; Sequence variants (SVs); Splicing sites (SS); V erb b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2)

Indexed keywords

DNA FRAGMENT; FORMALDEHYDE; GENOMIC DNA; PARAFFIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST LESION; CANCER PROGNOSIS; CAT; CONTROLLED STUDY; DNA EXTRACTION; ERBB2 GENE; EXON; FROZEN SECTION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC TRAIT; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME; HAPLOTYPE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; RNA SPLICING; TISSUE SECTION; TUMOR VOLUME; VETERINARY MEDICINE; ALTERNATIVE RNA SPLICING; ANIMAL; DNA SEQUENCE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; GENOTYPE; HUMAN; MOLECULAR GENETICS; PATHOLOGY;

ANIMALIA;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CATS; FEMALE; GENES, ERBB-2; GENOTYPE; HAPLOTYPES; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MOLECULAR SEQUENCE DATA; RECEPTOR, ERBB-2; SEQUENCE ANALYSIS, DNA;

EID: 84858964993     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13032783     Document Type: Article

References (54)

1. MacEwen, E.G. Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990, 9, 125-136.
2. Vail, D.M.; MacEwen, E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18, 781-792.
3. Zappulli, V.; de Zan, G.; Cardazzo, B.; Bargelloni, L.; Castagnaro, M. Feline mammary tumors in comparative oncology. J. Dairy Res. 2005, 72, 98-106.
4. Weijer, K.; Hart, A.A.M. Prognostic Factors in feline mammary carcinoma. J. Natl. Cancer Inst. 1983, 70, 709-716.
5. Hahn, K.A.; Bravo, L.; Avenell, J.S. Feline breast carcinoma as a pathologic and therapeutic model for human breast cancer. In Vivo 1994, 8, 825-828.
6. de Maria, R.; Olivero, M.; Iussich, S.; Nakaichi, M.; Murata, T.; Biolatti, B.; di Renzo, M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65, 907-912.
7. Burrai, G.P.; Mohammed, S.I.; Miller, M.A.; Marras, V.; Pirino, S.; Addis, M.F.; Uzzau, S.; Antuofermo, E. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10, doi:10.1186/1471-2407-10-156.
8. Lana, S.E.; Rutteman, G.R.; Withrow, S.J. Tumors of the Mammary Gland. In Small Animal Clinical Oncology, 4th ed.; Withrow, S.J., Vail, D.M., Eds.; Saunders Elsevier: Toronto, Canada, 2001; pp. 628-636.
9. Gimenez, F.; Hecht, S.; Craig, L.E.; Legendre, A.M. Early detection, aggressive therapy. Optimizing the management of feline mammary masses. J. Feline Med. Surg. 2010, 12, 214-224.
10. Owen, L.N. Classification of Tumors in Domestic Animals, 1st ed.; World Health Organization: Geneva, Belgium, 1980.
11. Ito, T.; Kadosawa, T.; Mochizuki, M.; Matsunaga, S.; Nishimura, R.; Sasaki, N. Prognosis of malignant mammary tumors in 53 cats. J. Vet. Med. Sci. 1996, 58, 723-726.
12. Winston, J.; Craft, D.M.; Scase, T.J.; Bergman, P.J. Immunohistochemical detection of erbB-2/neu expression in spontaneous feline mammary tumors. Vet. Comp. Oncol. 2005, 3, 8-15.
13. Ross, J.S.; Slodkowska, E.A.; Symmans, W.F.; Pusztai, L.; Ravnin, P.M.; Hortobagyi, G.N. The erbB-2 receptor and breast cancer: Ten years of targeted anti-erbB-2 therapy and personalized medicine. Oncologist 2009, 14, 320-368.
14. Tao, W.; Wang, C.; Han, R.; Jiang, H. HER2 codon 655 polymorphism and breast cancer risk: A meta-analysis. Breast Cancer Res. Treat. 2009, 114, 371-376
15. Penuel, E.; Schaefer, G.; Akita, R.W.; Sliwkowski, M.X. Structural requirements for ERBB2 transactivation. Semin. Oncol. 2001, 28, 36-42.
16. Benusiglio, P.R. Focus on ERBB2. Pharmaogenomics 2007, 9, 825-828.
17. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; et al. Studies of the erbB-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
18. Kolibaba, K.S.; Druker, B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1997, 1333, 217-248.
19. Ordás, J.; Millán, Y.; Dios, R.; Reymundo, C.; de las Mulas, J.M. Proto-oncogene erbB-2 in normal, dysplastic and tumorous feline mammary glands: An immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7, doi:10.1186/1471-2407-7-179.
20. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355-365.
21. Borg, A.; Tandon, A.K.; Sigurdsson, H.; Clark, G.M.; Fernö, M.; Fuqua, S.A.W.; Killander, D.; McGuire, W.L. ErbB-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990, 50, 4332-4337.
22. Charpin, C.; Garcia, S.; Bouvier, C.; Martini, F.; Lavaut, M.N.; Allasia, C.; Bonnier, P.; Andrac, L. C-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br. J. Cancer 1997, 75, 1667-1673.
23. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069-1075.
24. Leary, R.J.; Lin, J.C.; Cummins, J.; Boca, S.; Wood, L.D.; Parsons, D.W.; Jones, S.; Sjöblom, T.; Park, B.H.; Parsons, R.; et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 2008, 105, 16224-16229.
25. Benusiglio, P.R.; Lesueur, F.; Luccarini, C.; Conroy, D.M.; Shah, M.; Easton, D.F.; Day, N.E.; Dunning, A.M.; Pharoah, P.D.; Ponder, B.A. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: A case-control study. Breast Cancer Res. 2005, 7, 204-209.
26. Han, W.; Kang, D.; Lee, J.E.; Park, I.A.; Choi, J.Y.; Lee, K.M.; Bae, J.Y.; Kim, S.; Shin, E.S.; Lee, J.E.; et al. A haplotype analysis of erbB-2 gene polymorphisms: Association with breast cancer risk, erbB-2 protein expression in the tumor, and disease recurrence in Korea. Clin. Cancer Res. 2005, 11, 4775-4778.
27. Breyer, J.P.; Sanders, M.E.; Airey, D.C.; Cai, Q.; Yaspan, B.L.; Schuyler, P.A.; Dai, Q.; Boulos, F.; Olivares, M.G.; Bradley, K.M.; et al. Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1252-1258.
28. Desmet, F.O.; Hamroun, D.; Lalande, M.; Collod-Béroud, G.; Claustres, M.; Béroud, C. Human splicing finder: An online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009, 37, doi:10.1093/nar/gkp215.
29. Mayr, B.; Schaffner, G.; Kurzbauer, R.; Reifinger, M.; Schellander, K. Sequence of an exon of tumor suppressor p53 gene-A comparative study in domestic animals: Mutation in a feline solid mammary carcinoma. Br. Vet. J. 1995, 151, 325-329.
30. Mayr, B.; Reifinger, M.; Alton, K.; Schaffner, G. Novel p53 tumor suppressor mutations in cases of spindle cell sarcoma, pleomorphic sarcoma and fibrosarcoma in cats. Vet. Res. Commun. 1998, 22, 249-255.
31. Mayr, B.; Blauensteiner, J.; Edlinger, A.; Reifinger, M.; Alton, K.; Schaffner, G.; Brem, G. Presence of p53 mutations in feline neoplasms. Res. Vet. Sci. 2000, 68, 63-70.
32. Baptista, C.S.; Santos, S.; Laso, A.; Bastos, E.; Ávila, S.; Guedes-Pinto, H.; Gärtner, F.; Gut, I.G.; Castrillo, J.L.; Chaves, R. Sequence variation and mRNA expression of the TWIST1 gene in cats with mammary hyperplasia and neoplasia. Vet. J. 2011, 191, 203-207.
33. Nelson, S.E.; Gould, M.N.; Hampton, J.M. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res. 2005, 7, R357-R364.
34. Beauclair, S.; Formento, P.; Fischel, J.L.; Lescaut, W.; Largillier, R.; Chamorey, E.; Hofman, P.; Ferrero, J.M.; Pagès, G.; Milano, G. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann. Oncol. 2007, 18, 1335-1341.
35. Puputti, M.; Sihto, H.; Isola, J.; Butzow, R.; Joensuu, H.; Nupponen, N.N. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet. Cytogenet. 2006, 167, 32-38.
36. Jo, U.H.; Han, S.G.L.; Seo, J.H.; Park, K.H.; Lee, J.W.; Lee, H.J.; Ryu, J.S.; Kim, Y.H. The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. BMC Cancer 2008, 8, doi:10.1186/1471-2407-8-359.
37. Fleishman, S.J.; Schlessinger, J.; Ben-Tal, N. A putative molecular-activation switch in the transmembrane domain of ERBB2. Proc. Natl. Acad. Sci. USA 2002, 99, 15937-15940.
38. Bennasroune, A.; Fickova, M.; Gardin, A.; Dirrig-Grosch, S.; Aunis, D.; Cremel, G.; Hubert, P. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol. Biol. Cell 2004, 15, 3464-3474.
39. Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Genetic instabilities in human cancers. Nature 1998, 396, 643-649.
40. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992, 71, 543-546.
41. Bauer-Mehren, A.; Furlong, L.I.; Rautschka, M.; Sanz, F. From SNPs to pathways: Integration of functional effect of sequence variations on models of cell signaling pathways. BMC Bioinform. 2009, 10, doi:10.1186/1471-2105-10-S8-S6.
42. Venables, J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64, 7647-7654.
43. Loretti, A.P.; Ilha, M.R.; Ordas, J.; Martindelas Mulas, J. Clinical, pathological and immunohistochemical study of feline mammary fibro epithelial hyperplasia following a single injection of depot medroxyprogesterone acetate. J. Feline Med. Surg. 2005, 7, 43-52.
44. Rutteman, G.R.; Misdorp, W. Hormonal background of canine and feline mammary tumors. J. Reprod. Fertil. Suppl. 1993, 47, 483-487.
45. Hahn, K.A.; Bravo, L.; Avenell, J.S. Feline breast carcinoma as a pathologic and therapeutic model for human breast cancer. In Vivo 1994, 8, 825-828.
46. Hampe, J.F.; Misdorp, W. Tumours and dysplasias of the mammary gland. Bull. World Health Organ. 1974, 50, 111-133.
47. MacEwen, E.G.; Hayes, A.A.; Harvey, H.J.; Patnaik, A.K.; Mooney, S.; Passe, S. Prognostic factors for feline mammary tumors. J. Am. Vet. Med. Assoc. 1984, 2, 201-204.
48. Viste, J.R.; Myers, S.L.; Singh, B.; Simko, E. Feline mammary adenocarcinoma: Tumor size as a prognostic indicator. Can. Vet. J. 2002, 43, 33-37.
49. Misdorp, W.; Else, R.W.; Helmén, E.; Lipscomb, T.P. Histological Classification of Mammary Tumors of the Dog and Cat; Armed Forces Institute of Pathology and World Health Organization: Washington, DC, USA, 1999.
50. Santos, S.; Sá, D.; Bastos, E.; Guedes-Pinto, H.; Gut, I.; Gärtner, F.; Chaves, R. An efficient protocol for genomic DNA extraction from formalin-fixed paraffin-embedded tissues. Res. Vet. Sci. 2009, 86, 421-426.
51. den Dunnen, J.T.; Antonarakis, S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: A Discussion. Hum. Mutat. 2000, 15, 7-12.
52. den Dunnen, J.T.; Antonarakis, S.E. Nomenclature for the description of human sequence variations. Hum Genet. 2001, 109, 121-124.
53. Ogino, S.; Gulley, M.L.; den Dunnen, J.T.; Wilson, R.B. Association for molecular pathology training and education committee. Standard mutation nomenclature in molecular diagnostics. practical and educational challenges. J. Mol. Diagn. 2007, 9, 1-6.
54. Tommasi, S.; Fedele, V.; Lacalamita, R.; Crapolicchioa, A.; Perlinob, E.; Bellizia, A.; Paradiso, A. Molecular and functional characteristics of ERBB2 in normal and cancer breast cells. Cancer Lett. 2004, 209, 215-222.